MétaCan
Menu
Back to cohort
Record W4397007301 · doi:10.1016/j.esmoop.2024.103220

198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009

2024· article· en· W4397007301 on OpenAlexaff
Antonio Llombart‐Cussac, H.S. Rugo, Mark E. Robson, S-A. Im, F. Dalenc, Eduardo Yañez Ruiz, F.A. Reyes, J.M. Walshe, Y-H Im, Svitlana Kulyk, Alexander S. Dudnichenko, N. Llinas, Shigehira Saji, A. Bardia, N. Harbeck, Amin Haiderali, L. Fan, Allison Martin Nguyen, J.A. Mejia, David W. Cescon

Bibliographic record

VenueESMO Open · 2024
Typearticle
Languageen
FieldMedicine
TopicPARP inhibition in cancer therapy
Canadian institutionsPrincess Margaret Cancer Centre
FundersGenentechJapanese Society of Medical OncologyDaewoong Pharmaceutical CompanyChugai PharmaceuticalSeagenRadius HealthGilead SciencesEisaiDaiichi Sankyo EuropeSanofiAmgenPfizerLes Laboratories Pierre FabreAstraZenecaEli Lilly and Company
KeywordsPembrolizumabMedicineChemotherapyOlaparibOncologyInternal medicineImmunotherapyCancerPolymerase

Abstract

fetched live from OpenAlex

The phase II KEYLYNK-009 (NCT04191135) study evaluated maintenance pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy (chemo) in patients (pts) with metastatic TNBC who had clinical benefit from induction with first-line pembro + chemo. We present patient-reported outcomes (PROs) from this study to provide important evidence on the benefit/risk profile of these treatments. Eligible pts received induction therapy with pembro 200 mg Q3W + chemo (carboplatin AUC 2 + gemcitabine 1000 mg/m2 on days 1 and 8 per 21-day cycle) for 4–6 cycles. Pts with CR, PR, or SD were randomized 1:1 to pembro 200 mg Q3W + ola 300 mg BID or pembro + chemo (induction regimen) for up to 35 cycles (including induction). PROs were secondary endpoints and included changes from randomization (baseline) to week 18 (last time with completion/compliance ∼≥60%/80% in QLQ-C30) for EORTC QLQ-C30 GHS/QoL, QLQ-C30 physical and emotional functioning, QLQ-BR23 systemic therapy side effects, and EQ-5D-5L visual analogue scale (VAS). TTD (time from baseline to first onset of a confirmed ≥10-point deterioration) was also assessed. PROs were analyzed in randomized and treated pts who completed ≥1 PRO assessment. No alpha was assigned to PRO analyses. PRO analyses included 267 pts (pembro + ola, n = 135; pembro + chemo, n = 132). Completion/compliance in QLQ-C30 at week 18 was 59.3%/88.9% with pembro + ola and 62.1%/85.4% with pembro + chemo. No between-group differences were observed, except that TTD for QLQ-C30 GHS/QoL favored pembro + chemo (Table).Table: 198PBetween-group difference in change from baseline to wk 18 least-squares mean (95% CI)a (Pembro + Ola vs Pembro + Chemo)QLQ-C30 GHS/QoL−3.28 (−7.69 to 1.12)QLQ-C30 physical functioning−0.16 (−4.89 to 4.56)QLQ-C30 emotional functioning2.08 (−3.16 to 7.31)QLQ-BR23 systemic therapy side effects0.93 (−2.20 to 4.06)EQ-5D-5L VAS−0.37 (−4.03 to 3.28)TTD HR (95% CI)b (Pembro + Ola vs Pembro + Chemo)QLQ-C30 GHS/QoL1.78 (1.16–2.71)QLQ-C30 physical functioning1.01 (0.61–1.69)QLQ-C30 emotional functioning1.08 (0.69–1.71)QLQ-BR23 systemic therapy side effects1.76 (0.88–3.53)aBased on a constrained longitudinal data analysis model (cLDA).bBased on stratified Cox regression model. Open table in a new tab aBased on a constrained longitudinal data analysis model (cLDA). bBased on stratified Cox regression model. In pts with metastatic TNBC, stopping chemo in pts with responding or stable disease and treating with maintenance pembro + ola showed similar PRO results when compared with pts who continue pembro + chemo.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Insufficient payload (model declined to judge)
Consensus categoriesMeta-epidemiology (narrow)
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.468
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.001
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0060.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.045
GPT teacher head0.336
Teacher spread0.291 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; both teacher heads agree on what is shown here.

Study designRandomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueESMO OpenSame topicPARP inhibition in cancer therapyFrench-language works237,207